Saturday, July 11, 2026

Drug profile · INN

thioridazine

thioridazine (MELLARIL-S) is a d2-like dopamine receptor antagonist. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — thioridazine
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

thioridazine (MELLARIL-S) is a d2-like dopamine receptor antagonist. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN thioridazine
Brand MELLARIL-S
Mechanism D2-like dopamine receptor antagonist
Target D2-like dopamine receptor
Route ORAL
Formulation SUSPENSION

Mechanism of action

D2-like dopamine receptor antagonist

Primary target: D2-like dopamine receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. chlorpromazine hydrochloride D2-like dopamine receptor antagonist
  2. droperidol D2-like dopamine receptor antagonist
  3. haloperidol Serotonin 2a (5-HT2a) receptor antagonist
  4. haloperidol decanoate D2-like dopamine receptor inverse agonist
  5. haloperidol lactate Serotonin 2a (5-HT2a) receptor antagonist
  6. loxapine hydrochloride D2-like dopamine receptor antagonist

Frequently asked questions

What is thioridazine?

thioridazine (MELLARIL-S) is a d2-like dopamine receptor antagonist. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for thioridazine?

MELLARIL-S is a marketed brand name for thioridazine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of thioridazine?

thioridazine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.